Could a pill supercharge brain stimulation for depression?
NCT ID NCT07227103
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a drug called NRX-101 (a mix of D-cycloserine and lurasidone) to transcranial magnetic stimulation (TMS) helps people with treatment-resistant depression more than TMS alone. About 400 adults who have not had TMS before will receive either the drug or a placebo alongside a one-day TMS session. Researchers will measure depression and suicidal thoughts after six weeks to see if the combination improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION (TRD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cohen and Associates
Sarasota, Florida, 34239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
HOPE Accelerated Care
West Palm Beach, Florida, 33417, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harvard Mclean Hospital
Belmont, Massachusetts, 02478, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NRX-101 (D-cycloserine and lurasidone)
What this could lead to
If successful, this could provide a more effective treatment option for people with treatment-resistant depression, potentially doubling response and remission rates compared to TMS alone.
What could go wrong
This is an early-stage trial (Phase 2/3) with 400 participants, so results may not apply to everyone. The combination drug may cause side effects, and the placebo group also receives TMS, so the added benefit of NRX-101 is uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.